Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

Ascentage aims to raise $149 mln via US IPO Plans to offer 7.3 mln American depositary shares at $20.34 each Company's shares already listed in Hong Kong Jan 21 (Reuters) - Ascentage Pharma (6855 ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss treatment. Novo had set a target for patients to lose 25% of their body weight on average over 68 weeks.

Well, it was the age-old bane of pharma firms, namely disappointing late-stage clinical trial results. In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss ...

The team believes that the structure was in use until the 8th century BCE, the middle of the period when the Kings of Judah ruled. A scarab seal from the 8th century BCE uncovered during the ...

The most prescribed GLP-1 drugs include Ozempic, Wegovy, Mounjaro, CagriSema and Rybelsus. Salty snacks are seeing a slight decline but weren’t on the list of top products experiencing spending ...

Expectations have gotten so high that Novo Nordisk’s stock actually dropped when it announced that their drug candidate CagriSema (a mix of semaglutide with the experimental drug cagrilintide ...

CagriSema (cagrilintide + semaglutide) developed by Novo Nordisk|obesity and type 2 diabetes mellitus. CagriSema, combining cagrilintide, a long-acting amylin analog, with semaglutide, promises ...